4.2 Review

Positive GABAA receptor modulating steroids and their antagonists: Implications for clinical treatments

Journal

JOURNAL OF NEUROENDOCRINOLOGY
Volume 34, Issue 2, Pages -

Publisher

WILEY
DOI: 10.1111/jne.13013

Keywords

allopregnanolone; GABA(A) receptor modulating steroid antagonists; isoallopregnanolone

Funding

  1. EU-Grant [721802]
  2. Marie Curie Actions (MSCA) [721802] Funding Source: Marie Curie Actions (MSCA)

Ask authors/readers for more resources

GABA is the main inhibitory neurotransmitter in the brain, and Allopregnanolone (Allo) is a steroid that modulates the GABA(A) receptor, affecting mood, memory, and food intake. While Allo is generally considered to be anxiolytic and anti-depressant, studies have shown that it may have paradoxical effects in certain individuals. A new substance, Isoallopregnanolone (Isoallo), has been discovered to function as a GABA(A) receptor modulating steroid antagonist (GAMSA).
GABA is the main inhibitory neurotransmitter in the brain and GABAergic transmission has been shown to be of importance for regulation of mood, memory and food intake. The progesterone metabolite allopregnanolone (Allo) is a positive GABA(A) receptor modulating steroid with potent effects. In humans, disorders such as premenstrual dysphoric disorder (PMDD), hepatic encephalopathy and polycystic ovarian syndrome are associated with elevated Allo levels and increased negative mood, disturbed memory and increased food intake in some individuals. This is surprising because Allo shares many properties with benzodiazepines and is mainly considered to be anxiolytic and anti-depressant. However, it is well established that, in certain individuals, GABA(A) receptor activating compounds could have paradoxical effects and thus be anxiogenic in low physiological plasma concentrations but anxiolytic at high levels. We have demonstrated that isoallopregnanolone (Isoallo), the 3 beta-OH sibling of Allo, functions as a GABA(A) receptor modulating steroid antagonist (GAMSA) but without any effects of its own on GABA(A) receptors. The antagonistic effect is noted in most GABA(A) subtypes investigated in vitro to date. In vivo, Isoallo can inhibit Allo-induced anaesthesia in rats, as well as sedation or saccadic eye velocity in humans. Isoallo treatment has been studied in women with PMDD. In a first phase II study, Isoallo (Sepranolone; Asarina Pharma) injections significantly ameliorated negative mood in women with PMDD compared with placebo. Several GAMSAs for oral administration have also been developed. The GAMSA, UC1011, can inhibit Allo induced memory disturbances in rats and an oral GAMSA, GR3027, has been shown to restore learning and motor coordination in rats with hepatic encephalopathy. In humans, vigilance, cognition and pathological electroencephalogram were improved in patients with hepatic encephalopathy on treatment with GR3027. In conclusion GAMSAs are a new possible treatment for disorders and symptoms caused by hyperactivity in the GABA(A) system.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available